Gilenya and Zyvox (Linezolid Suspension)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using fingolimod together with linezolid may increase the risk of serious and potentially life-threatening infections. Because fingolimod can stay in your blood for a prolonged period after the last dose, interactions with other drugs may occur for some time even after you have stopped taking it. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues. When administered daily, fingolimod produces a dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values, which may increase the risk of infections. A small study consisting of 12 subjects receiving fingolimod 0.5 mg daily found that lymphocyte count decreased to approximately 60% of baseline within 4 to 6 hours after the first dose and continued to decrease over a 2-week period, reaching a nadir count of approximately 500 cells/mcL, or 30% of baseline. In a placebo-controlled study of 1272 multiple sclerosis patients, 18% of patients on fingolimod 0.5 mg daily reached a nadir of less than 200 cells/mcL on at least one occasion, compared to no patient on placebo. Decreased lymphocyte counts persist during daily dosing and generally return to baseline within 1 to 2 months after stopping the medication. In addition, a mild decrease in the neutrophil count to approximately 80% of baseline occurs during chronic therapy. Serious infections requiring admission to hospital have been reported.

MANAGEMENT: The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available. Treatment suspension should be considered in patients who develop a serious infection, and the benefits and risks reassessed prior to restarting treatment. Because fingolimod remains in the blood for up to two months after the last dose, continued monitoring is recommended throughout this period, and initiating other drugs during this period warrants the same considerations needed for concomitant administration. Likewise, caution should be applied when switching patients from long-acting therapies with immune effects such as natalizumab or mitoxantrone.

Gilenya

Generic Name: fingolimod

Brand name: Gilenya

Synonyms: n.a.

What is Gilenya?

Zyvox (Linezolid Suspension)

Generic Name: linezolid

Brand name: Zyvox

Synonyms: Zyvox

What is Zyvox (Linezolid Suspension)?